Resveratrol - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (25)Enzymes (4)Carriers (2)

Targets (25)Enzymes (4)Carriers (2)Biointeractions (11)

Identification

Name

Resveratrol

Accession Number

DB02709 (EXPT02968)

Type

Small Molecule

Groups

Experimental, Investigational

Description

Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as two structural isomers: cis-(Z) and trans-(E), with the trans-isomer shown in the top image. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of Science, Dr. Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation. It has been claimed that it is readily degraded by exposure to light, heat, and oxygen. However, studies find that Trans-resveratrol undergoes negligible oxidation in normal atmosphere at room temperature.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol

(E)-resveratrol

3,4',5-trihydroxy-trans-stilbene

3,4',5-trihydroxystilbene

3,5,4'-trihydroxystilbene

5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol

trans-resveratrol

External IDs

Not Available

Product Ingredients

Not Available

Approved Prescription Products

Not Available

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Not Available

Brand mixtures

Name	Labeller	Ingredients
Co-veratrol	Home Aide Diganostics, Inc.	Folic Acid Methylcobalamin Resveratrol Ubiquinol

Categories

UNII

Q369O8926L

CAS number

501-36-0

Weight

Average: 228.2433
Monoisotopic: 228.07864425

Chemical Formula

C₁₄H₁₂O₃

InChI Key

LUKBXSAWLPMMSZ-OWOJBTEDSA-N

InChI

InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+

IUPAC Name

5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol

SMILES

OC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1

Pharmacology

Indication

Being investigated for the treatment of Herpes labialis infections (cold sores).

Structured Indications

Not Available

Pharmacodynamics

Resveratrol, a phytoalexin, has been found to inhibit herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) replication in a dose-dependent, reversible manner, although this is only one of its many pharmaceutical properties. In some countries where there is higher consumption of red wine, there appears to be a lower incidence of heart disease. Other benefits of resveratrol include its anti-inflammatory and antioxidant effects. In preclinical studies, Resveratrol has been found to have potential anticancer properties.

Mechanism of action

Resveratrol suppresses NF-kappaB (NF-kappaB) activation in HSV infected cells. Reports have indicated that HSV activates NF-kappaB during productive infection and this may be an essential aspect of its replication scheme [PMID: 9705914].

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Ribosyldihydronicotinamide dehydrogenase [quinone]	Protein	unknown	Not Available	Human	P16083	details
Casein kinase II subunit alpha	Protein	unknown	Not Available	Human	P68400	details
Prostaglandin G/H synthase 1	Protein	unknown	inhibitor	Human	P23219	details
Prostaglandin G/H synthase 2	Protein	unknown	inhibitor	Human	P35354	details
Arachidonate 15-lipoxygenase	Protein	unknown	Not Available	Human	P16050	details
Arachidonate 5-lipoxygenase	Protein	unknown	Not Available	Human	P09917	details
Aryl hydrocarbon receptor	Protein	unknown	Not Available	Human	P35869	details
Phosphatidylinositol 4-kinase type 2-beta	Protein	unknown	Not Available	Human	Q8TCG2	details
Integrin alpha-5	Protein	unknown	Not Available	Human	P08648	details
Integrin beta-3	Protein	unknown	Not Available	Human	P05106	details
Amyloid beta A4 protein	Protein	unknown	Not Available	Human	P05067	details
Alpha-synuclein	Protein	unknown	Not Available	Human	P37840	details
Estrogen receptor	Protein	unknown	Not Available	Human	P03372	details
Melatonin receptor type 1A	Protein	unknown	Not Available	Human	P48039	details
Melatonin receptor type 1B	Protein	unknown	Not Available	Human	P49286	details
C-type lectin domain family 14 member A	Protein	unknown	Not Available	Human	Q86T13	details
Nuclear receptor subfamily 1 group I member 2	Protein	unknown	Not Available	Human	O75469	details
Nuclear receptor subfamily 1 group I member 3	Protein	unknown	Not Available	Human	Q14994	details
Solute carrier family 2, facilitated glucose transporter member 1	Protein	unknown	Not Available	Human	P11166	details
Carbonyl reductase [NADPH] 1	Protein	unknown	inhibitor	Human	P16152	details
Peroxisome proliferator-activated receptor alpha	Protein	unknown	Not Available	Human	Q07869	details
Peroxisome proliferator-activated receptor gamma	Protein	unknown	Not Available	Human	P37231	details
RAC-alpha serine/threonine-protein kinase	Protein	unknown	inhibitor	Human	P31749	details
Far upstream element-binding protein 2	Protein	unknown	Not Available	Human	Q92945	details
Tyrosine--tRNA ligase, cytoplasmic	Protein	unknown	inhibitor	Human	P54577	details

Absorption

High absorption but very low bioavailability.

Volume of distribution

Not Available

Protein binding

Strong affinity towards protein binding.

Metabolism

Hepatic. Rapidly metabolized and excreted.

Substrate	Enzymes	Product
Resveratrol	Cytochrome P450 1A2	piceatannol (3,5,3',4'-tetrahydroxystilbene)	Details
Resveratrol	Cytochrome P450 1A2	tetrahydroxystilbene M1	Details

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
16-Bromoepiandrosterone	The risk or severity of adverse effects can be increased when Resveratrol is combined with 16-Bromoepiandrosterone.	Investigational
19-norandrostenedione	The risk or severity of adverse effects can be increased when Resveratrol is combined with 19-norandrostenedione.	Experimental, Illicit
5-androstenedione	The risk or severity of adverse effects can be increased when Resveratrol is combined with 5-androstenedione.	Experimental, Illicit
Abciximab	Resveratrol may increase the anticoagulant activities of Abciximab.	Approved
Abiraterone	The serum concentration of Resveratrol can be increased when it is combined with Abiraterone.	Approved
Acebutolol	Resveratrol may decrease the antihypertensive activities of Acebutolol.	Approved
Aceclofenac	The risk or severity of adverse effects can be increased when Resveratrol is combined with Aceclofenac.	Approved
Acenocoumarol	Resveratrol may increase the anticoagulant activities of Acenocoumarol.	Approved
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Resveratrol.	Approved
Acetylsalicylic acid	The risk or severity of adverse effects can be increased when Resveratrol is combined with Acetylsalicylic acid.	Approved, Vet Approved
Aclarubicin	Resveratrol may decrease the excretion rate of Aclarubicin which could result in a higher serum level.	Investigational
Adapalene	The risk or severity of adverse effects can be increased when Adapalene is combined with Resveratrol.	Approved
Alclometasone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Alclometasone.	Approved
Aldosterone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Aldosterone.	Experimental
Alendronic acid	The risk or severity of adverse effects can be increased when Resveratrol is combined with Alendronic acid.	Approved
Aliskiren	Resveratrol may decrease the antihypertensive activities of Aliskiren.	Approved, Investigational
Alprenolol	Resveratrol may decrease the antihypertensive activities of Alprenolol.	Approved, Withdrawn
Alprostadil	The therapeutic efficacy of Alprostadil can be decreased when used in combination with Resveratrol.	Approved, Investigational
Alteplase	Resveratrol may increase the anticoagulant activities of Alteplase.	Approved
Amcinonide	The risk or severity of adverse effects can be increased when Resveratrol is combined with Amcinonide.	Approved
Amikacin	Resveratrol may decrease the excretion rate of Amikacin which could result in a higher serum level.	Approved, Vet Approved
Amiloride	Resveratrol may decrease the antihypertensive activities of Amiloride.	Approved
Aminosalicylic Acid	The risk or severity of adverse effects can be increased when Resveratrol is combined with Aminosalicylic Acid.	Approved
Amrubicin	Resveratrol may decrease the excretion rate of Amrubicin which could result in a higher serum level.	Approved, Investigational
Anagrelide	Resveratrol may increase the anticoagulant activities of Anagrelide.	Approved
Ancrod	Resveratrol may increase the anticoagulant activities of Ancrod.	Investigational
Andrographolide	The risk or severity of adverse effects can be increased when Resveratrol is combined with HMPL-004.	Investigational
Androstenedione	The risk or severity of adverse effects can be increased when Resveratrol is combined with 4-Androstenedione.	Experimental, Illicit
Anecortave	The risk or severity of adverse effects can be increased when Resveratrol is combined with Anecortave.	Investigational
Anisodamine	The risk or severity of adverse effects can be increased when Resveratrol is combined with Anisodamine.	Investigational
Anistreplase	Resveratrol may increase the anticoagulant activities of Anistreplase.	Approved
Antipyrine	The risk or severity of adverse effects can be increased when Antipyrine is combined with Resveratrol.	Approved
Antithrombin III human	Resveratrol may increase the anticoagulant activities of Antithrombin III human.	Approved
Apixaban	The risk or severity of adverse effects can be increased when Resveratrol is combined with Apixaban.	Approved
Apocynin	The risk or severity of adverse effects can be increased when Resveratrol is combined with Acetovanillone.	Investigational
Apramycin	Resveratrol may decrease the excretion rate of Apramycin which could result in a higher serum level.	Experimental, Vet Approved
Apremilast	The risk or severity of adverse effects can be increased when Resveratrol is combined with Apremilast.	Approved, Investigational
Arbekacin	Resveratrol may decrease the excretion rate of Arbekacin which could result in a higher serum level.	Approved
Ardeparin	Resveratrol may increase the anticoagulant activities of Ardeparin.	Approved, Withdrawn
Argatroban	Resveratrol may increase the anticoagulant activities of Argatroban.	Approved, Investigational
Arotinolol	Resveratrol may decrease the antihypertensive activities of Arotinolol.	Approved
Atenolol	Resveratrol may decrease the antihypertensive activities of Atenolol.	Approved
Azapropazone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Azapropazone.	Withdrawn
Azelastine	The risk or severity of adverse effects can be increased when Azelastine is combined with Resveratrol.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Resveratrol.	Approved
Azithromycin	The metabolism of Resveratrol can be decreased when combined with Azithromycin.	Approved
Balsalazide	Resveratrol may increase the nephrotoxic activities of Balsalazide.	Approved, Investigational
Becaplermin	Resveratrol may increase the anticoagulant activities of Becaplermin.	Approved, Investigational
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Resveratrol is combined with Beclomethasone dipropionate.	Approved, Investigational
Befunolol	Resveratrol may decrease the antihypertensive activities of Befunolol.	Experimental
Bemiparin	Resveratrol may increase the anticoagulant activities of Bemiparin.	Approved
Benazepril	The risk or severity of adverse effects can be increased when Benazepril is combined with Resveratrol.	Approved, Investigational
Bendroflumethiazide	The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Resveratrol.	Approved
Benoxaprofen	The risk or severity of adverse effects can be increased when Resveratrol is combined with Benoxaprofen.	Withdrawn
Beraprost	The therapeutic efficacy of Beraprost can be decreased when used in combination with Resveratrol.	Investigational
Betamethasone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Betamethasone.	Approved, Vet Approved
Betaxolol	Resveratrol may decrease the antihypertensive activities of Betaxolol.	Approved
Betulinic Acid	The risk or severity of adverse effects can be increased when Resveratrol is combined with Betulinic Acid.	Investigational
Bevacizumab	Bevacizumab may increase the cardiotoxic activities of Resveratrol.	Approved, Investigational
Bevantolol	Resveratrol may decrease the antihypertensive activities of Bevantolol.	Approved
Bimatoprost	The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Resveratrol.	Approved, Investigational
Bisoprolol	Resveratrol may decrease the antihypertensive activities of Bisoprolol.	Approved
Bivalirudin	Resveratrol may increase the anticoagulant activities of Bivalirudin.	Approved, Investigational
Bopindolol	Resveratrol may decrease the antihypertensive activities of Bopindolol.	Approved
Bortezomib	The metabolism of Resveratrol can be decreased when combined with Bortezomib.	Approved, Investigational
Bromfenac	The risk or severity of adverse effects can be increased when Bromfenac is combined with Resveratrol.	Approved
Bucillamine	The risk or severity of adverse effects can be increased when Resveratrol is combined with Bucillamine.	Investigational
Bucindolol	Resveratrol may decrease the antihypertensive activities of Bucindolol.	Investigational
Budesonide	The risk or severity of adverse effects can be increased when Resveratrol is combined with Budesonide.	Approved
Bufuralol	Resveratrol may decrease the antihypertensive activities of Bufuralol.	Experimental, Investigational
Bumetanide	Resveratrol may decrease the diuretic activities of Bumetanide.	Approved
Bupranolol	Resveratrol may decrease the antihypertensive activities of Bupranolol.	Approved
Butylphthalide	Resveratrol may increase the antiplatelet activities of Butylphthalide.	Investigational
Cabazitaxel	The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Resveratrol.	Approved
Caffeine	The metabolism of Resveratrol can be decreased when combined with Caffeine.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Candesartan is combined with Resveratrol.	Approved
Candoxatril	The risk or severity of adverse effects can be increased when Candoxatril is combined with Resveratrol.	Experimental
Cangrelor	Resveratrol may increase the anticoagulant activities of Cangrelor.	Approved
Captopril	The risk or severity of adverse effects can be increased when Captopril is combined with Resveratrol.	Approved
Carbamazepine	The metabolism of Resveratrol can be increased when combined with Carbamazepine.	Approved, Investigational
Carboprost Tromethamine	The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Resveratrol.	Approved
Carprofen	The risk or severity of adverse effects can be increased when Carprofen is combined with Resveratrol.	Approved, Vet Approved, Withdrawn
Carteolol	Resveratrol may decrease the antihypertensive activities of Carteolol.	Approved
Carvedilol	Resveratrol may decrease the antihypertensive activities of Carvedilol.	Approved, Investigational
Castanospermine	The risk or severity of adverse effects can be increased when Castanospermine is combined with Resveratrol.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Resveratrol is combined with Celecoxib.	Approved, Investigational
Celiprolol	Resveratrol may decrease the antihypertensive activities of Celiprolol.	Approved, Investigational
Certoparin	Resveratrol may increase the anticoagulant activities of Certoparin.	Approved
Chloroquine	The risk or severity of adverse effects can be increased when Chloroquine is combined with Resveratrol.	Approved, Vet Approved
Chlorothiazide	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Resveratrol.	Approved, Vet Approved
Chlorthalidone	The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Resveratrol.	Approved
Cholestyramine	Cholestyramine can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Choline magnesium trisalicylate	The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Resveratrol.	Approved
Ciclesonide	The risk or severity of adverse effects can be increased when Resveratrol is combined with Ciclesonide.	Approved, Investigational
Cilazapril	The risk or severity of adverse effects can be increased when Cilazapril is combined with Resveratrol.	Approved
Cilostazol	Resveratrol may increase the anticoagulant activities of Cilostazol.	Approved
Cinoxacin	Resveratrol may increase the neuroexcitatory activities of Cinoxacin.	Approved, Withdrawn
Ciprofloxacin	Resveratrol may increase the neuroexcitatory activities of Ciprofloxacin.	Approved, Investigational
Citalopram	The metabolism of Resveratrol can be decreased when combined with Citalopram.	Approved
Citric Acid	Resveratrol may increase the anticoagulant activities of Citric Acid.	Nutraceutical, Vet Approved
Clobetasol	The risk or severity of adverse effects can be increased when Resveratrol is combined with Clobetasol.	Investigational
Clobetasol propionate	The risk or severity of adverse effects can be increased when Resveratrol is combined with Clobetasol propionate.	Approved
Clocortolone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Clocortolone.	Approved
Clodronic Acid	The risk or severity of adverse effects can be increased when Resveratrol is combined with Clodronate.	Approved, Investigational, Vet Approved
Clonixin	The risk or severity of adverse effects can be increased when Resveratrol is combined with Clonixin.	Approved
Clopidogrel	Resveratrol may increase the anticoagulant activities of Clopidogrel.	Approved, Nutraceutical
Clotrimazole	The metabolism of Resveratrol can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Colesevelam	Colesevelam can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colestipol	Colestipol can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Cortisone acetate	The risk or severity of adverse effects can be increased when Resveratrol is combined with Cortisone acetate.	Approved
Curcumin	The risk or severity of adverse effects can be increased when Resveratrol is combined with Curcumin.	Investigational
Cyclophosphamide	Cyclophosphamide may increase the cardiotoxic activities of Resveratrol.	Approved, Investigational
Cyclosporine	Resveratrol may increase the nephrotoxic activities of Cyclosporine.	Approved, Investigational, Vet Approved
Cyproterone acetate	The serum concentration of Resveratrol can be decreased when it is combined with Cyproterone acetate.	Approved, Investigational
Dabigatran etexilate	Resveratrol may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Dalteparin	Resveratrol may increase the anticoagulant activities of Dalteparin.	Approved
Darexaban	Resveratrol may increase the anticoagulant activities of Ym150.	Investigational
Dasatinib	Dasatinib may increase the anticoagulant activities of Resveratrol.	Approved, Investigational
Daunorubicin	Resveratrol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.	Approved
Deferasirox	The risk or severity of adverse effects can be increased when Resveratrol is combined with Deferasirox.	Approved, Investigational
Defibrotide	Resveratrol may increase the anticoagulant activities of Defibrotide.	Approved, Investigational
Deoxycholic Acid	The risk or severity of adverse effects can be increased when Resveratrol is combined with Deoxycholic Acid.	Approved
Desirudin	Resveratrol may increase the anticoagulant activities of Desirudin.	Approved
Deslanoside	Deslanoside may decrease the cardiotoxic activities of Resveratrol.	Approved
Desmopressin	The risk or severity of adverse effects can be increased when Resveratrol is combined with Desmopressin.	Approved
Desmoteplase	Resveratrol may increase the anticoagulant activities of Desmoteplase.	Investigational
Desoximetasone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Desoximetasone.	Approved
Desoxycorticosterone Pivalate	The risk or severity of adverse effects can be increased when Resveratrol is combined with Desoxycorticosterone Pivalate.	Experimental, Vet Approved
Dexamethasone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexketoprofen	The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Resveratrol.	Approved
Dextran	Resveratrol may increase the anticoagulant activities of Dextran.	Approved, Vet Approved
Dextran 40	Resveratrol may increase the anticoagulant activities of Dextran 40.	Approved
Diclofenac	The risk or severity of adverse effects can be increased when Diclofenac is combined with Resveratrol.	Approved, Vet Approved
Dicoumarol	Resveratrol may increase the anticoagulant activities of Dicoumarol.	Approved
Diflorasone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Diflorasone.	Approved
Diflunisal	The risk or severity of adverse effects can be increased when Resveratrol is combined with Diflunisal.	Approved
Difluocortolone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Difluocortolone.	Approved
Difluprednate	The risk or severity of adverse effects can be increased when Resveratrol is combined with Difluprednate.	Approved
Digitoxin	Digitoxin may decrease the cardiotoxic activities of Resveratrol.	Approved
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Resveratrol.	Approved
Dinoprost	The therapeutic efficacy of Dinoprost can be decreased when used in combination with Resveratrol.	Investigational
Dinoprost Tromethamine	The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Resveratrol.	Approved, Vet Approved
Dinoprostone	The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Resveratrol.	Approved
Dipyridamole	Resveratrol may increase the anticoagulant activities of Dipyridamole.	Approved
Ditazole	Resveratrol may increase the anticoagulant activities of Ditazole.	Approved, Withdrawn
Docetaxel	The risk or severity of adverse effects can be increased when Docetaxel is combined with Resveratrol.	Approved, Investigational
Doxorubicin	Resveratrol may decrease the excretion rate of Doxorubicin which could result in a higher serum level.	Approved, Investigational
Drospirenone	Resveratrol may increase the hyperkalemic activities of Drospirenone.	Approved
Drotrecogin alfa	Resveratrol may increase the anticoagulant activities of Drotrecogin alfa.	Approved, Investigational, Withdrawn
Droxicam	The risk or severity of adverse effects can be increased when Resveratrol is combined with Droxicam.	Approved
Duvelisib	The risk or severity of adverse effects can be increased when Resveratrol is combined with Duvelisib.	Investigational
E-6201	The risk or severity of adverse effects can be increased when Resveratrol is combined with E6201.	Investigational
Ebselen	The risk or severity of adverse effects can be increased when Resveratrol is combined with Ebselen.	Investigational
Edetic Acid	Resveratrol may increase the anticoagulant activities of Edetic Acid.	Approved, Vet Approved
Edoxaban	Resveratrol may increase the anticoagulant activities of Edoxaban.	Approved
Enalapril	The risk or severity of adverse effects can be increased when Enalapril is combined with Resveratrol.	Approved, Vet Approved
Enalaprilat	The risk or severity of adverse effects can be increased when Enalaprilat is combined with Resveratrol.	Approved
Enoxacin	Resveratrol may increase the neuroexcitatory activities of Enoxacin.	Approved
Enoxaparin	Resveratrol may increase the anticoagulant activities of Enoxaparin.	Approved
Epinastine	Epinastine may increase the antiplatelet activities of Resveratrol.	Approved, Investigational
Epirizole	The risk or severity of adverse effects can be increased when Resveratrol is combined with Epirizole.	Approved
Epirubicin	Resveratrol may decrease the excretion rate of Epirubicin which could result in a higher serum level.	Approved
Eplerenone	Resveratrol may decrease the antihypertensive activities of Eplerenone.	Approved
Epoprostenol	Epoprostenol may increase the antiplatelet activities of Resveratrol.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Eprosartan is combined with Resveratrol.	Approved
Eptifibatide	Resveratrol may increase the anticoagulant activities of Eptifibatide.	Approved, Investigational
Equilenin	The risk or severity of adverse effects can be increased when Resveratrol is combined with Equilenin.	Experimental
Equilin	The risk or severity of adverse effects can be increased when Resveratrol is combined with Equilin.	Approved
Esmolol	Resveratrol may decrease the antihypertensive activities of Esmolol.	Approved
Estrone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Estrone.	Approved
Estrone sulfate	The risk or severity of adverse effects can be increased when Resveratrol is combined with Estrone sulfate.	Approved
Etacrynic acid	Resveratrol may decrease the diuretic activities of Etacrynic acid.	Approved
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Resveratrol.	Approved, Investigational
Ethyl biscoumacetate	Resveratrol may increase the anticoagulant activities of Ethyl biscoumacetate.	Withdrawn
Etidronic acid	The risk or severity of adverse effects can be increased when Resveratrol is combined with Etidronic acid.	Approved
Etodolac	The risk or severity of adverse effects can be increased when Resveratrol is combined with Etodolac.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of adverse effects can be increased when Resveratrol is combined with Etofenamate.	Approved
Etoricoxib	The risk or severity of adverse effects can be increased when Resveratrol is combined with Etoricoxib.	Approved, Investigational
Fenbufen	The risk or severity of adverse effects can be increased when Resveratrol is combined with Fenbufen.	Approved
Fenoprofen	The risk or severity of adverse effects can be increased when Fenoprofen is combined with Resveratrol.	Approved
Fibrinolysin	Resveratrol may increase the anticoagulant activities of Plasmin.	Investigational
Fleroxacin	Resveratrol may increase the neuroexcitatory activities of Fleroxacin.	Approved
Floctafenine	The risk or severity of adverse effects can be increased when Floctafenine is combined with Resveratrol.	Approved, Withdrawn
Fludrocortisone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Fludrocortisone.	Approved
Fluindione	Resveratrol may increase the anticoagulant activities of Fluindione.	Investigational
Flumequine	Resveratrol may increase the neuroexcitatory activities of Flumequine.	Withdrawn
Flumethasone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Flumethasone.	Approved, Vet Approved
Flunisolide	The risk or severity of adverse effects can be increased when Resveratrol is combined with Flunisolide.	Approved, Investigational
Fluocinolone Acetonide	The risk or severity of adverse effects can be increased when Resveratrol is combined with Fluocinolone Acetonide.	Approved, Investigational, Vet Approved
Fluocinonide	The risk or severity of adverse effects can be increased when Resveratrol is combined with Fluocinonide.	Approved, Investigational
Fluocortolone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Fluocortolone.	Approved, Withdrawn
Fluorometholone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Fluorometholone.	Approved
Fluprednidene	The risk or severity of adverse effects can be increased when Resveratrol is combined with Fluprednidene.	Approved, Withdrawn
Flurandrenolide	The risk or severity of adverse effects can be increased when Resveratrol is combined with Flurandrenolide.	Approved
Flurbiprofen	The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Resveratrol.	Approved, Investigational
Fluticasone furoate	The risk or severity of adverse effects can be increased when Resveratrol is combined with Fluticasone furoate.	Approved
Fluticasone propionate	The risk or severity of adverse effects can be increased when Resveratrol is combined with Fluticasone Propionate.	Approved
Fluvoxamine	The metabolism of Resveratrol can be decreased when combined with Fluvoxamine.	Approved, Investigational
Folic Acid	The therapeutic efficacy of Folic Acid can be decreased when used in combination with Resveratrol.	Approved, Nutraceutical, Vet Approved
Fondaparinux	Resveratrol may increase the anticoagulant activities of Fondaparinux.	Investigational
Fondaparinux sodium	Resveratrol may increase the anticoagulant activities of Fondaparinux sodium.	Approved, Investigational
Forasartan	The risk or severity of adverse effects can be increased when Forasartan is combined with Resveratrol.	Experimental
Formestane	The risk or severity of adverse effects can be increased when Resveratrol is combined with Formestane.	Approved, Investigational, Withdrawn
Fosinopril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Resveratrol.	Approved
Framycetin	Resveratrol may decrease the excretion rate of Framycetin which could result in a higher serum level.	Approved
Furosemide	Resveratrol may decrease the diuretic activities of Furosemide.	Approved, Vet Approved
Gabexate	Resveratrol may increase the anticoagulant activities of Gabexate.	Investigational
Gatifloxacin	Resveratrol may increase the neuroexcitatory activities of Gatifloxacin.	Approved, Investigational
Gemeprost	The therapeutic efficacy of Gemeprost can be decreased when used in combination with Resveratrol.	Approved, Withdrawn
Gemifloxacin	Resveratrol may increase the neuroexcitatory activities of Gemifloxacin.	Approved, Investigational
Geneticin	Resveratrol may decrease the excretion rate of Geneticin which could result in a higher serum level.	Experimental
Gentamicin	Resveratrol may decrease the excretion rate of Gentamicin which could result in a higher serum level.	Approved, Vet Approved
GENTAMICIN C1A	Resveratrol may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.	Experimental
Glucosamine	Glucosamine may increase the antiplatelet activities of Resveratrol.	Approved
Grepafloxacin	Resveratrol may increase the neuroexcitatory activities of Grepafloxacin.	Withdrawn
Haloperidol	The risk or severity of adverse effects can be increased when Resveratrol is combined with Haloperidol.	Approved
HE3286	The risk or severity of adverse effects can be increased when Resveratrol is combined with HE3286.	Investigational
Heparin	Resveratrol may increase the anticoagulant activities of Heparin.	Approved, Investigational
Higenamine	Resveratrol may increase the anticoagulant activities of Higenamine.	Investigational
Hydralazine	Resveratrol may decrease the antihypertensive activities of Hydralazine.	Approved
Hydrochlorothiazide	The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Resveratrol.	Approved, Vet Approved
Hydrocortisone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Hydrocortisone.	Approved, Vet Approved
Hydroflumethiazide	The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Resveratrol.	Approved
Ibandronate	The risk or severity of adverse effects can be increased when Resveratrol is combined with Ibandronate.	Approved, Investigational
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Resveratrol is combined with Ibritumomab tiuxetan.	Approved
Ibrutinib	The risk or severity of adverse effects can be increased when Ibrutinib is combined with Resveratrol.	Approved
Ibudilast	Resveratrol may increase the antiplatelet activities of Ibudilast.	Approved, Investigational
Ibuprofen	The risk or severity of adverse effects can be increased when Ibuprofen is combined with Resveratrol.	Approved
Ibuproxam	The risk or severity of adverse effects can be increased when Resveratrol is combined with Ibuproxam.	Withdrawn
Icatibant	The risk or severity of adverse effects can be increased when Resveratrol is combined with Icatibant.	Approved
Icosapent ethyl	Resveratrol may increase the antiplatelet activities of Icosapent ethyl.	Approved, Nutraceutical
Idarubicin	Resveratrol may decrease the excretion rate of Idarubicin which could result in a higher serum level.	Approved
Ifenprodil	Resveratrol may increase the antiplatelet activities of Ifenprodil.	Approved, Withdrawn
Iloprost	Iloprost may increase the antiplatelet activities of Resveratrol.	Approved, Investigational
Imidapril	The risk or severity of adverse effects can be increased when Imidapril is combined with Resveratrol.	Investigational
Indapamide	The therapeutic efficacy of Indapamide can be decreased when used in combination with Resveratrol.	Approved
Indenolol	Resveratrol may decrease the antihypertensive activities of Indenolol.	Withdrawn
Indobufen	Resveratrol may increase the anticoagulant activities of Indobufen.	Investigational
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Resveratrol.	Approved, Investigational
Indoprofen	The risk or severity of adverse effects can be increased when Resveratrol is combined with Indoprofen.	Withdrawn
Irbesartan	The risk or severity of adverse effects can be increased when Irbesartan is combined with Resveratrol.	Approved, Investigational
Isoxicam	The risk or severity of adverse effects can be increased when Resveratrol is combined with Isoxicam.	Withdrawn
Kanamycin	Resveratrol may decrease the excretion rate of Kanamycin which could result in a higher serum level.	Approved, Vet Approved
Kebuzone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Kebuzone.	Experimental
Ketanserin	Resveratrol may increase the antiplatelet activities of Ketanserin.	Investigational
Ketoprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Resveratrol.	Approved, Vet Approved
Ketorolac	The risk or severity of adverse effects can be increased when Ketorolac is combined with Resveratrol.	Approved
Labetalol	Resveratrol may decrease the antihypertensive activities of Labetalol.	Approved
Landiolol	Resveratrol may decrease the antihypertensive activities of Aop200704.	Investigational
Latanoprost	The therapeutic efficacy of Latanoprost can be decreased when used in combination with Resveratrol.	Approved, Investigational
Leflunomide	The risk or severity of adverse effects can be increased when Leflunomide is combined with Resveratrol.	Approved, Investigational
Lepirudin	Resveratrol may increase the anticoagulant activities of Lepirudin.	Approved
Levobunolol	Resveratrol may decrease the antihypertensive activities of Levobunolol.	Approved
Levofloxacin	Resveratrol may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Lidocaine	The metabolism of Resveratrol can be decreased when combined with Lidocaine.	Approved, Vet Approved
Limaprost	Limaprost may increase the antiplatelet activities of Resveratrol.	Approved
Lisinopril	The risk or severity of adverse effects can be increased when Lisinopril is combined with Resveratrol.	Approved, Investigational
Lisofylline	The risk or severity of adverse effects can be increased when Resveratrol is combined with Lisofylline.	Investigational
Lithium	The serum concentration of Lithium can be increased when it is combined with Resveratrol.	Approved
Lomefloxacin	Resveratrol may increase the neuroexcitatory activities of Lomefloxacin.	Approved
Lornoxicam	The risk or severity of adverse effects can be increased when Resveratrol is combined with Lornoxicam.	Approved
Losartan	The risk or severity of adverse effects can be increased when Losartan is combined with Resveratrol.	Approved
Loxoprofen	The risk or severity of adverse effects can be increased when Resveratrol is combined with Loxoprofen.	Approved
Lubiprostone	The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Resveratrol.	Approved, Investigational
Lumiracoxib	The risk or severity of adverse effects can be increased when Resveratrol is combined with Lumiracoxib.	Approved, Investigational
Magnesium salicylate	The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Resveratrol.	Approved
Masoprocol	The risk or severity of adverse effects can be increased when Masoprocol is combined with Resveratrol.	Approved
ME-609	The risk or severity of adverse effects can be increased when Resveratrol is combined with ME-609.	Investigational
Meclofenamic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Resveratrol.	Approved, Vet Approved
Medrysone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Medrysone.	Approved
Mefenamic acid	The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Resveratrol.	Approved
Meloxicam	The risk or severity of adverse effects can be increased when Meloxicam is combined with Resveratrol.	Approved, Vet Approved
Mesalazine	The risk or severity of adverse effects can be increased when Resveratrol is combined with Mesalazine.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Resveratrol is combined with Metamizole.	Withdrawn
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Resveratrol.	Approved
Methyclothiazide	The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Resveratrol.	Approved
Methylprednisolone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Methylprednisolone.	Approved, Vet Approved
Metipranolol	Resveratrol may decrease the antihypertensive activities of Metipranolol.	Approved
Metolazone	The therapeutic efficacy of Metolazone can be decreased when used in combination with Resveratrol.	Approved
Metoprolol	Resveratrol may decrease the antihypertensive activities of Metoprolol.	Approved, Investigational
Metrizamide	Resveratrol may decrease the excretion rate of Metrizamide which could result in a higher serum level.	Approved
Mexiletine	The metabolism of Resveratrol can be decreased when combined with Mexiletine.	Approved
Milrinone	Milrinone may increase the antiplatelet activities of Resveratrol.	Approved
Misoprostol	The therapeutic efficacy of Misoprostol can be decreased when used in combination with Resveratrol.	Approved
Mizoribine	The risk or severity of adverse effects can be increased when Resveratrol is combined with Mizoribine.	Investigational
Moexipril	The risk or severity of adverse effects can be increased when Moexipril is combined with Resveratrol.	Approved
Mometasone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Mometasone.	Approved, Vet Approved
Morniflumate	The risk or severity of adverse effects can be increased when Morniflumate is combined with Resveratrol.	Approved
Moxifloxacin	Resveratrol may increase the neuroexcitatory activities of Moxifloxacin.	Approved, Investigational
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Resveratrol.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Resveratrol.	Approved
Nabumetone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Nabumetone.	Approved
Nadolol	Resveratrol may decrease the antihypertensive activities of Nadolol.	Approved
Nadroparin	Resveratrol may increase the anticoagulant activities of Nadroparin.	Approved
Nafamostat	Resveratrol may increase the anticoagulant activities of Nafamostat.	Approved, Investigational
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with Resveratrol.	Approved
Naftopidil	Resveratrol may increase the antiplatelet activities of Naftopidil.	Investigational
Nalidixic Acid	Resveratrol may increase the neuroexcitatory activities of Nalidixic Acid.	Approved
Naproxen	The risk or severity of adverse effects can be increased when Naproxen is combined with Resveratrol.	Approved, Vet Approved
NCX 1022	The risk or severity of adverse effects can be increased when Resveratrol is combined with NCX 1022.	Investigational
NCX 4016	The risk or severity of adverse effects can be increased when Resveratrol is combined with NCX 4016.	Investigational
Neamine	Resveratrol may decrease the excretion rate of Neamine which could result in a higher serum level.	Experimental
Neomycin	Resveratrol may decrease the excretion rate of Neomycin which could result in a higher serum level.	Approved, Vet Approved
Nepafenac	The risk or severity of adverse effects can be increased when Resveratrol is combined with Nepafenac.	Approved
Netilmicin	Resveratrol may decrease the excretion rate of Netilmicin which could result in a higher serum level.	Approved
Nevirapine	The metabolism of Resveratrol can be decreased when combined with Nevirapine.	Approved
Niflumic Acid	The risk or severity of adverse effects can be increased when Resveratrol is combined with Niflumic Acid.	Approved
Nimesulide	The risk or severity of adverse effects can be increased when Resveratrol is combined with Nimesulide.	Approved, Withdrawn
Nitroaspirin	The risk or severity of adverse effects can be increased when Resveratrol is combined with Nitroaspirin.	Investigational
Norfloxacin	Resveratrol may increase the neuroexcitatory activities of Norfloxacin.	Approved
Obinutuzumab	The risk or severity of adverse effects can be increased when Resveratrol is combined with Obinutuzumab.	Approved
Ofloxacin	Resveratrol may increase the neuroexcitatory activities of Ofloxacin.	Approved
Oleandrin	Anvirzel may decrease the cardiotoxic activities of Resveratrol.	Experimental
Oleoyl-estrone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Oleoyl estrone.	Investigational
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Resveratrol.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Olopatadine is combined with Resveratrol.	Approved
Olsalazine	Resveratrol may increase the nephrotoxic activities of Olsalazine.	Approved
Omacetaxine mepesuccinate	The risk or severity of adverse effects can be increased when Resveratrol is combined with Omacetaxine mepesuccinate.	Approved
Omapatrilat	The risk or severity of adverse effects can be increased when Omapatrilat is combined with Resveratrol.	Investigational
Omega-3 fatty acids	Omega-3 fatty acids may increase the antiplatelet activities of Resveratrol.	Approved, Nutraceutical
Osimertinib	The serum concentration of Resveratrol can be decreased when it is combined with Osimertinib.	Approved
Ouabain	Ouabain may decrease the cardiotoxic activities of Resveratrol.	Approved
Oxaprozin	The risk or severity of adverse effects can be increased when Oxaprozin is combined with Resveratrol.	Approved
Oxprenolol	Resveratrol may decrease the antihypertensive activities of Oxprenolol.	Approved
Oxyphenbutazone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Oxyphenbutazone.	Withdrawn
Ozagrel	Resveratrol may increase the anticoagulant activities of Kct 0809.	Investigational
Paclitaxel	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Resveratrol.	Approved, Vet Approved
Pamidronate	The risk or severity of adverse effects can be increased when Resveratrol is combined with Pamidronate.	Approved
Paramethasone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Paramethasone.	Approved
Parecoxib	The risk or severity of adverse effects can be increased when Resveratrol is combined with Parecoxib.	Approved
Parnaparin	Resveratrol may increase the anticoagulant activities of Parnaparin.	Approved
Paromomycin	Resveratrol may decrease the excretion rate of Paromomycin which could result in a higher serum level.	Approved, Investigational
Pazufloxacin	Resveratrol may increase the neuroexcitatory activities of Pazufloxacin.	Investigational
Pefloxacin	Resveratrol may increase the neuroexcitatory activities of Pefloxacin.	Approved
Peginterferon alfa-2b	The serum concentration of Resveratrol can be increased when it is combined with Peginterferon alfa-2b.	Approved
Penbutolol	Resveratrol may decrease the antihypertensive activities of Penbutolol.	Approved, Investigational
Pentosan Polysulfate	The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Resveratrol.	Approved
Pentoxifylline	Pentoxifylline may increase the antiplatelet activities of Resveratrol.	Approved, Investigational
Perindopril	The risk or severity of adverse effects can be increased when Perindopril is combined with Resveratrol.	Approved
Phenindione	Resveratrol may increase the anticoagulant activities of Phenindione.	Approved
Phenobarbital	The metabolism of Resveratrol can be increased when combined with Phenobarbital.	Approved
Phenprocoumon	Resveratrol may increase the anticoagulant activities of Phenprocoumon.	Approved
Phenylbutazone	The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Resveratrol.	Approved, Vet Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Resveratrol.	Approved, Investigational
Pindolol	Resveratrol may decrease the antihypertensive activities of Pindolol.	Approved
Pirarubicin	Resveratrol may decrease the excretion rate of Pirarubicin which could result in a higher serum level.	Investigational
Piretanide	Resveratrol may decrease the diuretic activities of Piretanide.	Experimental
Pirfenidone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Pirfenidone.	Investigational
Piroxicam	The risk or severity of adverse effects can be increased when Piroxicam is combined with Resveratrol.	Approved, Investigational
Plicamycin	Resveratrol may decrease the excretion rate of Plicamycin which could result in a higher serum level.	Approved, Withdrawn
Polythiazide	The therapeutic efficacy of Polythiazide can be decreased when used in combination with Resveratrol.	Approved
Practolol	Resveratrol may decrease the antihypertensive activities of Practolol.	Approved
Pralatrexate	The serum concentration of Pralatrexate can be increased when it is combined with Resveratrol.	Approved
Prasterone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Prasterone.	Approved, Nutraceutical
Prasterone sulfate	The risk or severity of adverse effects can be increased when Resveratrol is combined with dehydroepiandrosterone sulfate.	Investigational
Prasugrel	Resveratrol may increase the anticoagulant activities of Prasugrel.	Approved
Prednicarbate	The risk or severity of adverse effects can be increased when Resveratrol is combined with Prednicarbate.	Approved
Prednisolone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Prednisolone.	Approved, Vet Approved
Prednisone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Prednisone.	Approved, Vet Approved
Pregnenolone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Pregnenolone.	Experimental
Primidone	The metabolism of Resveratrol can be increased when combined with Primidone.	Approved, Vet Approved
Probenecid	The serum concentration of Resveratrol can be increased when it is combined with Probenecid.	Approved
Propacetamol	The risk or severity of adverse effects can be increased when Resveratrol is combined with Propacetamol.	Approved
Propranolol	Resveratrol may decrease the antihypertensive activities of Propranolol.	Approved, Investigational
Prostaglandin B2	The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Resveratrol.	Experimental
Prostaglandin G2	The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Resveratrol.	Experimental
Protein S human	Resveratrol may increase the anticoagulant activities of Protein S human.	Approved
Prulifloxacin	Resveratrol may increase the neuroexcitatory activities of Prulifloxacin.	Investigational
PTC299	The risk or severity of adverse effects can be increased when Resveratrol is combined with PTC299.	Investigational
Puromycin	Resveratrol may decrease the excretion rate of Puromycin which could result in a higher serum level.	Experimental
Quinapril	The risk or severity of adverse effects can be increased when Quinapril is combined with Resveratrol.	Approved, Investigational
Quinethazone	The therapeutic efficacy of Quinethazone can be decreased when used in combination with Resveratrol.	Approved
Ramatroban	Resveratrol may increase the antiplatelet activities of Ramatroban.	Investigational
Ramipril	The risk or severity of adverse effects can be increased when Ramipril is combined with Resveratrol.	Approved
Rescinnamine	The risk or severity of adverse effects can be increased when Rescinnamine is combined with Resveratrol.	Approved
Reteplase	Resveratrol may increase the anticoagulant activities of Reteplase.	Approved
Reviparin	Resveratrol may increase the anticoagulant activities of Reviparin.	Approved
Ribostamycin	Resveratrol may decrease the excretion rate of Ribostamycin which could result in a higher serum level.	Approved
Ridogrel	Ridogrel may increase the antiplatelet activities of Resveratrol.	Approved
Rifampicin	The metabolism of Resveratrol can be increased when combined with Rifampicin.	Approved
Rimexolone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Rimexolone.	Approved
Risedronate	The risk or severity of adverse effects can be increased when Resveratrol is combined with Risedronate.	Approved, Investigational
Rivaroxaban	Resveratrol may increase the anticoagulant activities of Rivaroxaban.	Approved
Rofecoxib	The risk or severity of adverse effects can be increased when Resveratrol is combined with Rofecoxib.	Investigational, Withdrawn
Ropinirole	The metabolism of Resveratrol can be decreased when combined with Ropinirole.	Approved, Investigational
Rosiglitazone	Resveratrol may increase the anticoagulant activities of Rosiglitazone.	Approved, Investigational
Rosoxacin	Resveratrol may increase the neuroexcitatory activities of Rosoxacin.	Approved
Sacubitril	The risk or severity of adverse effects can be increased when Sacubitril is combined with Resveratrol.	Approved
Salicylamide	The risk or severity of adverse effects can be increased when Resveratrol is combined with Salicylamide.	Approved
Salicylic acid	The risk or severity of adverse effects can be increased when Resveratrol is combined with Salicylic acid.	Approved, Vet Approved
Salsalate	The risk or severity of adverse effects can be increased when Salsalate is combined with Resveratrol.	Approved
Saprisartan	The risk or severity of adverse effects can be increased when Saprisartan is combined with Resveratrol.	Experimental
Selexipag	Resveratrol may increase the anticoagulant activities of Selexipag.	Approved
Sevoflurane	Sevoflurane may increase the antiplatelet activities of Resveratrol.	Approved, Vet Approved
Simeprevir	The metabolism of Resveratrol can be decreased when combined with Simeprevir.	Approved
Sisomicin	Resveratrol may decrease the excretion rate of Sisomicin which could result in a higher serum level.	Investigational
Sotalol	Resveratrol may decrease the antihypertensive activities of Sotalol.	Approved
SP1049C	Resveratrol may decrease the excretion rate of SP1049C which could result in a higher serum level.	Investigational
Sparfloxacin	Resveratrol may increase the neuroexcitatory activities of Sparfloxacin.	Approved
Spectinomycin	Resveratrol may decrease the excretion rate of Spectinomycin which could result in a higher serum level.	Approved, Vet Approved
Spirapril	The risk or severity of adverse effects can be increased when Spirapril is combined with Resveratrol.	Approved
Spironolactone	Resveratrol may decrease the antihypertensive activities of Spironolactone.	Approved
SRT501	The risk or severity of adverse effects can be increased when Resveratrol is combined with SRT501.	Investigational
Streptokinase	Resveratrol may increase the anticoagulant activities of Streptokinase.	Approved
Streptomycin	Resveratrol may decrease the excretion rate of Streptomycin which could result in a higher serum level.	Approved, Vet Approved
Streptozocin	Resveratrol may decrease the excretion rate of Streptozocin which could result in a higher serum level.	Approved
Sulfasalazine	Resveratrol may increase the nephrotoxic activities of Sulfasalazine.	Approved
Sulindac	The risk or severity of adverse effects can be increased when Sulindac is combined with Resveratrol.	Approved
Sulodexide	Resveratrol may increase the anticoagulant activities of Sulodexide.	Approved, Investigational
Sulprostone	The therapeutic efficacy of Sulprostone can be decreased when used in combination with Resveratrol.	Investigational
Suprofen	The risk or severity of adverse effects can be increased when Suprofen is combined with Resveratrol.	Approved, Withdrawn
Tacrolimus	Resveratrol may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Tafluprost	The therapeutic efficacy of Tafluprost can be decreased when used in combination with Resveratrol.	Approved
Talniflumate	The risk or severity of adverse effects can be increased when Talniflumate is combined with Resveratrol.	Approved
Tasosartan	The risk or severity of adverse effects can be increased when Tasosartan is combined with Resveratrol.	Approved
Technetium Tc-99m medronate	The risk or severity of adverse effects can be increased when Resveratrol is combined with Technetium Tc-99m Medronate.	Approved
Telmisartan	The risk or severity of adverse effects can be increased when Telmisartan is combined with Resveratrol.	Approved, Investigational
Temafloxacin	Resveratrol may increase the neuroexcitatory activities of Temafloxacin.	Withdrawn
Temocapril	The risk or severity of adverse effects can be increased when Temocapril is combined with Resveratrol.	Experimental, Investigational
Tenecteplase	Resveratrol may increase the anticoagulant activities of Tenecteplase.	Approved
Tenofovir disoproxil	The risk or severity of adverse effects can be increased when Resveratrol is combined with Tenofovir.	Approved, Investigational
Tenoxicam	The risk or severity of adverse effects can be increased when Tenoxicam is combined with Resveratrol.	Approved
Teriflunomide	The serum concentration of Resveratrol can be decreased when it is combined with Teriflunomide.	Approved
Tesmilifene	Resveratrol may increase the antiplatelet activities of Tesmilifene.	Investigational
Theophylline	The metabolism of Resveratrol can be decreased when combined with Theophylline.	Approved
Tiaprofenic acid	The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Resveratrol.	Approved
Ticagrelor	Resveratrol may increase the anticoagulant activities of Ticagrelor.	Approved
Ticlopidine	The metabolism of Resveratrol can be decreased when combined with Ticlopidine.	Approved
Tiludronic acid	The risk or severity of adverse effects can be increased when Resveratrol is combined with Tiludronate.	Approved, Vet Approved
Timolol	Resveratrol may decrease the antihypertensive activities of Timolol.	Approved
Tinoridine	The risk or severity of adverse effects can be increased when Resveratrol is combined with Tinoridine.	Investigational
Tinzaparin	Resveratrol may increase the anticoagulant activities of Tinzaparin.	Approved
Tipranavir	Tipranavir may increase the antiplatelet activities of Resveratrol.	Approved, Investigational
Tirofiban	Resveratrol may increase the anticoagulant activities of Tirofiban.	Approved
Tixocortol	The risk or severity of adverse effects can be increased when Resveratrol is combined with Tixocortol.	Approved
Tobramycin	Resveratrol may decrease the excretion rate of Tobramycin which could result in a higher serum level.	Approved, Investigational
Tolfenamic Acid	The risk or severity of adverse effects can be increased when Resveratrol is combined with Tolfenamic Acid.	Approved
Tolmetin	The risk or severity of adverse effects can be increased when Tolmetin is combined with Resveratrol.	Approved
Torasemide	Resveratrol may decrease the diuretic activities of Torasemide.	Approved
Tositumomab	The risk or severity of adverse effects can be increased when Resveratrol is combined with Tositumomab.	Approved
Trandolapril	The risk or severity of adverse effects can be increased when Trandolapril is combined with Resveratrol.	Approved
Tranilast	The risk or severity of adverse effects can be increased when Resveratrol is combined with Tranilast.	Approved, Investigational
Trapidil	Resveratrol may increase the antiplatelet activities of Trapidil.	Approved
Trastuzumab	Trastuzumab may increase the cardiotoxic activities of Resveratrol.	Approved, Investigational
Travoprost	The therapeutic efficacy of Travoprost can be decreased when used in combination with Resveratrol.	Approved
Treprostinil	The risk or severity of adverse effects can be increased when Treprostinil is combined with Resveratrol.	Approved, Investigational
Triamcinolone	The risk or severity of adverse effects can be increased when Resveratrol is combined with Triamcinolone.	Approved, Vet Approved
Triamterene	Resveratrol may decrease the antihypertensive activities of Triamterene.	Approved
Trichlormethiazide	The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Resveratrol.	Approved, Vet Approved
Triflusal	Resveratrol may increase the anticoagulant activities of Triflusal.	Approved
Trovafloxacin	Resveratrol may increase the neuroexcitatory activities of Trovafloxacin.	Approved, Withdrawn
Unoprostone	The therapeutic efficacy of Unoprostone can be decreased when used in combination with Resveratrol.	Approved
Urokinase	Resveratrol may increase the anticoagulant activities of Urokinase.	Approved, Investigational, Withdrawn
Valdecoxib	The risk or severity of adverse effects can be increased when Resveratrol is combined with Valdecoxib.	Investigational, Withdrawn
Valrubicin	Resveratrol may decrease the excretion rate of Valrubicin which could result in a higher serum level.	Approved
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Resveratrol.	Approved, Investigational
Vancomycin	The serum concentration of Vancomycin can be increased when it is combined with Resveratrol.	Approved
Vemurafenib	The serum concentration of Resveratrol can be increased when it is combined with Vemurafenib.	Approved
Vitamin E	Vitamin E may increase the antiplatelet activities of Resveratrol.	Approved, Nutraceutical, Vet Approved
Vorapaxar	Resveratrol may increase the anticoagulant activities of Vorapaxar.	Approved
Warfarin	Resveratrol may increase the anticoagulant activities of Warfarin.	Approved
Ximelagatran	Resveratrol may increase the anticoagulant activities of Ximelagatran.	Approved, Investigational, Withdrawn
Zaltoprofen	The risk or severity of adverse effects can be increased when Resveratrol is combined with Zaltoprofen.	Approved
Zileuton	The risk or severity of adverse effects can be increased when Zileuton is combined with Resveratrol.	Approved, Investigational, Withdrawn
Zoledronic acid	The risk or severity of adverse effects can be increased when Resveratrol is combined with Zoledronic acid.	Approved
Zomepirac	The risk or severity of adverse effects can be increased when Resveratrol is combined with Zomepirac.	Withdrawn
Zorubicin	Resveratrol may decrease the excretion rate of Zorubicin which could result in a higher serum level.	Experimental

Food Interactions

Not Available

References

Synthesis Reference

Philippe Jeandet, Roger Bessis, Marielle Adrian, Jean-Claude Yvin, Jean-Marie Joubert, "Use of aluminium chloride as a resveratrol synthesis elicitor." U.S. Patent US6080701, issued August, 1991.

US6080701

General References

Farina A, Ferranti C, Marra C: An improved synthesis of resveratrol. Nat Prod Res. 2006 Mar;20(3):247-52. [PubMed:16401555 ]
Renaud S, Ruf JC: The French paradox: vegetables or wine. Circulation. 1994 Dec;90(6):3118-9. [PubMed:7994864 ]
Wang Y, Catana F, Yang Y, Roderick R, van Breemen RB: An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J Agric Food Chem. 2002 Jan 30;50(3):431-5. [PubMed:11804508 ]
Lyons MM, Yu C, Toma RB, Cho SY, Reiboldt W, Lee J, van Breemen RB: Resveratrol in raw and baked blueberries and bilberries. J Agric Food Chem. 2003 Sep 24;51(20):5867-70. [PubMed:13129286 ]
Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK: High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004 Dec;32(12):1377-82. Epub 2004 Aug 27. [PubMed:15333514 ]
Csaki C, Keshishzadeh N, Fischer K, Shakibaei M: Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem Pharmacol. 2008 Feb 1;75(3):677-87. Epub 2007 Sep 18. [PubMed:17959154 ]
Docherty JJ, Fu MM, Stiffler BS, Limperos RJ, Pokabla CM, DeLucia AL: Resveratrol inhibition of herpes simplex virus replication. Antiviral Res. 1999 Oct;43(3):145-55. [PubMed:10551373 ]
N' soukpoe-Kossi CN, St-Louis C, Beauregard M, Subirade M, Carpentier R, Hotchandani S, Tajmir-Riahi HA: Resveratrol binding to human serum albumin. J Biomol Struct Dyn. 2006 Dec;24(3):277-83. [PubMed:17054386 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB03747
KEGG Compound	C03582
PubChem Compound	445154
PubChem Substance	46504705
ChemSpider	392875
BindingDB	23926
ChEBI	45713
ChEMBL	CHEMBL165
Therapeutic Targets Database	DNC001205
PharmGKB	PA165291838
HET	STL
Wikipedia	Resveratrol

ATC Codes

Not Available

AHFS Codes

Not Available

PDB Entries

1U0W

FDA label

Not Available

MSDS

Download (16.6 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Recruiting	Treatment	Diabetic Nephropathies	1
1	Active Not Recruiting	Treatment	Diastolic Heart Failure / Heart Failure With Preserved Ejection Fraction (HFpEF) / Hypertensive / Hypertensive Heart Disease / Oxidative Stress	1
1	Completed	Not Available	Memory	1
1	Completed	Basic Science	Healthy, no Evidence of Disease	1
1	Completed	Basic Science	Type 2 Diabetes Mellitus	1
1	Completed	Prevention	Healthy, no Evidence of Disease	1
1	Completed	Prevention	Unspecified Adult Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Adenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Stage I Colon Cancer / Stage I Rectal Cancer / Stage II Colon Cancer / Stage II Rectal Cancer / Stage III Colon Cancer / Stage III Rectal Cancer	1
1	Completed	Treatment	Cancers / Malignant Neoplasm of Colon	1
1	Completed	Treatment	Parkinson's Disease (PD)	4
1, 2	Completed	Treatment	Friedreich's Ataxia	1
2	Completed	Basic Science	Dyslipidemias / Insulin Resistance	1
2	Completed	Basic Science	Sedentary Lifestyle	1
2	Completed	Prevention	Schizophrenic Disorders	1
2	Completed	Treatment	Alzheimer's Disease (AD)	1
2	Completed	Treatment	BMI >30 kg/m2 / Diabetes	1
2	Completed	Treatment	Metabolic Syndromes	1
2	Recruiting	Supportive Care	Mitochondrial Function / Physical Function	1
2	Recruiting	Treatment	Aging	1
2	Recruiting	Treatment	Type 2 Diabetes Mellitus	1
2	Unknown Status	Treatment	Follicular Lymphoma (FL)	1
2	Unknown Status	Treatment	Insulin Resistance / Type 2 Diabetes Mellitus	1
2	Withdrawn	Treatment	Insulin Resistance	1
3	Enrolling by Invitation	Basic Science	Metabolic Syndromes	1
3	Not Yet Recruiting	Supportive Care	Osteoarthritis of the Knees / Primary Knee Osteoarthritis	1
4	Completed	Treatment	Endometriosis	1
4	Not Yet Recruiting	Treatment	Acute Pancreatitis (AP) / Gastrointestinal Diseases	1
Not Available	Completed	Prevention	Endothelial Disfunction / Lipid Metabolism Disorders / Vascular System Injuries	1
Not Available	Completed	Treatment	Peripheral Arterial Disease (PAD)	1
Not Available	Unknown Status	Not Available	Eye Disease	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Form	Route	Strength
Capsule	Oral

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	254 °C	PhysProp

Predicted Properties

Property	Value	Source
Water Solubility	0.0688 mg/mL	ALOGPS
logP	2.57	ALOGPS
logP	3.4	ChemAxon
logS	-3.5	ALOGPS
pKa (Strongest Acidic)	8.49	ChemAxon
pKa (Strongest Basic)	-6.2	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	3	ChemAxon
Polar Surface Area	60.69 Å²	ChemAxon
Rotatable Bond Count	2	ChemAxon
Refractivity	67.46 m³·mol^-1	ChemAxon
Polarizability	24.55 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9952
Blood Brain Barrier	+	0.59
Caco-2 permeable	+	0.8915
P-glycoprotein substrate	Non-substrate	0.6501
P-glycoprotein inhibitor I	Non-inhibitor	0.9266
P-glycoprotein inhibitor II	Non-inhibitor	0.9612
Renal organic cation transporter	Non-inhibitor	0.8634
CYP450 2C9 substrate	Non-substrate	0.7519
CYP450 2D6 substrate	Non-substrate	0.9288
CYP450 3A4 substrate	Non-substrate	0.7143
CYP450 1A2 substrate	Inhibitor	0.9106
CYP450 2C9 inhibitor	Inhibitor	0.7068
CYP450 2D6 inhibitor	Non-inhibitor	0.9226
CYP450 2C19 inhibitor	Inhibitor	0.8052
CYP450 3A4 inhibitor	Inhibitor	0.7539
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.8559
Ames test	Non AMES toxic	0.8407
Carcinogenicity	Non-carcinogens	0.7825
Biodegradation	Not ready biodegradable	0.8499
Rat acute toxicity	1.6791 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.8933
hERG inhibition (predictor II)	Non-inhibitor	0.9462

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
GC-MS	GC-MS Spectrum - GC-MS (3 TMS)	splash10-0006-1853900000-4919511a11ec24935434	View in MoNA
Predicted GC-MS	Predicted GC-MS Spectrum - GC-MS	Not Available
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ , negative	splash10-004i-0090000000-d9def7cee71fb7a40786	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ , negative	splash10-004r-0970000000-f8c7ca07f27bfc1b8bda	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ , negative	splash10-0006-0900000000-b1333b06db343c38f529	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ , negative	splash10-014l-0900000000-c856c7fa9653868e5785	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ , negative	splash10-004r-0950000000-8e44b9aa58ac75282058	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ , negative	splash10-000f-0900000000-2b750fcfd933ce8809f2	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-TOF , negative	splash10-014i-0900000000-79bf3bfcbb7bcdd0ffd2	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-TOF , negative	splash10-014i-0900000000-79bf3bfcbb7bcdd0ffd2	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-TOF , negative	splash10-014i-0900000000-9340e3fe04d435cf8475	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-TOF , negative	splash10-014i-0900000000-9340e3fe04d435cf8475	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-TOF , negative	splash10-004i-0590000000-4a9b53d6aad6ed8189d2	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-TOF , negative	splash10-004i-0590000000-4a9b53d6aad6ed8189d2	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-TOF , negative	splash10-00kf-0900000000-b0f6bf3388d96335d77e	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-TOF , negative	splash10-00kf-0900000000-b0f6bf3388d96335d77e	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-004i-0390000000-f19a725fa516c1ccd06d	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0a4r-1900000000-12ac653b70e86d051e9a	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0a4l-3900000000-cddc9dc871ae0131587d	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0aov-4900000000-085c30542d4dbecc9a30	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-004i-0390000000-f8caace8d6c937282e65	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.

Kingdom

Organic compounds

Super Class

Phenylpropanoids and polyketides

Class

Stilbenes

Sub Class

Not Available

Direct Parent

Stilbenes

Alternative Parents

Styrenes / Resorcinols / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Organooxygen compounds / Hydrocarbon derivatives

Substituents

Stilbene / Styrene / Resorcinol / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Benzenoid / Monocyclic benzene moiety / Organic oxygen compound / Hydrocarbon derivative

Molecular Framework

Aromatic homomonocyclic compounds

External Descriptors

resveratrol (CHEBI:45713 ) / Diphenyl ethers, biphenyls, dibenzyls and stilbenes, Stilbenes (C03582 ) / Diphenyl ethers, biphenyls, dibenzyls and stilbenes (LMPK13090005 )

Get DrugBank to go!

Structure for DB02709 (Resveratrol)

Targets

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

Enzymes

References

References

References

References

Carriers

References

References